Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Change in Receivables (2016 - 2025)

Lisata Therapeutics' Change in Receivables history spans 11 years, with the latest figure at -$3000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 100.33% year-over-year to -$3000.0; the TTM value through Dec 2025 reached -$401000.0, down 144.56%, while the annual FY2025 figure was -$401000.0, 144.56% down from the prior year.
  • Change in Receivables reached -$3000.0 in Q4 2025 per LSTA's latest filing, down from $1000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $900000.0 in Q4 2024 to a low of -$249000.0 in Q2 2025.